The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
An open-label, randomized phase II study comparing first-line treatment with dovitinib (TKI258) versus sorafenib in patients with advanced hepatocellular carcinoma.
Ann-Lii Cheng
Honoraria - Novartis
Ho Yeong Lim
No relevant relationships to disclose
Ronnie Tung Ping Poon
Consultant or Advisory Role - Novartis
Sumitra Throngprasert
Consultant or Advisory Role - Lilly (U); Novartis (U); Pfizer (U)
Honoraria - AstraZeneca; Roche
Research Funding - Novartis; Pfizer; Roche
Cathy Reddick
Employment or Leadership Position - Novartis
Stock Ownership - Novartis (B)
Yong Zhang
Employment or Leadership Position - Novartis
Michael Shi
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Eugene Tan
Employment or Leadership Position - Novartis
Yongyu Wang
Employment or Leadership Position - Novartis